Ono, Akira
Murakami, Haruyasu http://orcid.org/0000-0003-2416-546X
Seto, Takashi
Shimizu, Toshio
Watanabe, Sawori
Takeshita, Shigeru
Takeda, Kentaro
Toyoshima, Junko
Nagase, Itsuro
Bahceci, Erkut
Morishita, Maiko
Morita, Satoshi
Fukuoka, Masahiro
Nakagawa, Kazuhiko
Clinical trials referenced in this document:
Documents that mention this clinical trial
Treatment and detection of ALK-rearranged NSCLC
https://doi.org/10.1016/j.lungcan.2013.03.017
Safety and Antitumor Activity of Repeated ASP3026 Administration in Japanese Patients with Solid Tumors: A Phase I Study
https://doi.org/10.1007/s40268-020-00331-2
Drastic initial response and subsequent response to two ALK inhibitors in a patient with a highly aggressive ALK-rearranged inflammatory myofibroblastic tumor arising in the pleural cavity
https://doi.org/10.1016/j.lungcan.2016.07.002
Funding for this research was provided by:
Astellas Pharma Inc
Article History
Accepted: 20 November 2020
First Online: 17 December 2020
Declarations
:
: This study was funded by Astellas Pharma, Inc.
: Akira Ono has received honoraria from AstraZeneca, Ono Pharmaceutical, Chugai Pharmaceutical Co., Ltd., and MSD. Haruyasu Murakami has received honoraria from AstraZeneca and has received research funding from Astellas, AstraZeneca, Eli Lilly, and Taiho Pharmaceutical. Takashi Seto has received honoraria from AstraZeneca, Chugai Pharmaceutical, Eli Lilly Japan, Nippon Boehringer Ingelheim, Ono Pharmaceutical, Pfizer Japan, Taiho Pharmaceutical, and Merck Sharp & Dohme, and has received grants from Astellas Pharma, AstraZeneca, Chugai Pharmaceutical, Daiichi Sankyo, Eli Lilly Japan, Eisai, Kissei Pharmaceutical, Merck Serono, Merck Sharp & Dohme, Nippon Boehringer Ingelheim, Novartis, Pfizer Japan, Verastem, and Yakult Honsha. Toshio Shimizu has received research funds from Bristol-Myers Squibb, Daiichi Sankyo, Takeda-Millennium, Five Prime, PharmaMar, 3D Medicine, and SymBio Pharmaceuticals. Shigeru Takeshita, Kentaro Takeda, and Erkut Bahceci are employees of Astellas Pharma Global Development, Inc. Junko Toyoshima, Itsuro Nagase, and Maiko Morishita are employees of Astellas Pharma Inc. Satoshi Morita has received honoraria from AstraZeneca, Chugai, Bristol-Myers Squibb, and Eli Lilly, and has received research funds from Boehringer Ingelheim. Masahiro Fukuoka has received honoraria from Astellas Pharma Inc. Kazuhiko Nakagawa has received honoraria from Eli Lilly Japan K.K., AstraZeneca K.K., Pfizer Japan Inc., Astellas Pharma Inc., Nippon Boehringer Ingelheim Co., Ltd., MSD K.K., and Ono Pharmaceutical Co., Ltd. and has received research funds from MSD K.K., Quintiles Inc., Eisai Co., Ltd., Daiichi Sankyo Co., Ltd., AbbVie Inc., ICON Japan K.K., Eli Lilly Japan K.K., Bristol-Myers Squibb Company, Ono Pharmaceutical Co., Ltd., Taiho Pharmaceutical Co., Ltd., A2 Healthcare Corp., Astellas Pharma Inc., inVentiv Health Japan, AC Medical Inc., Gritstone Oncology Inc., Nippon Boehringer Ingelheim Co., Ltd., Takeda Pharmaceutical Co., Ltd., and Chugai Pharmaceutical Co., Ltd. Sawori Watanabe declares no conflict of interest. This study was sponsored by Astellas Pharma Inc (APGD Japan).
: This study was approved by the ethical review board of the participating institutions and posted on ClinicalTrials.gov under the identifier NCT01401504. All study procedures were conducted in accordance with the principles of the Declaration of Helsinki.
: All patients provided informed consent to participate in the study.
: Not applicable.
: Datasets from this study have not been made available in an open data repository.
: Akira Ono, Haruyasu Murakami, Toshio Shimizu, Takashi Seto, Sawori Watanabe and Kazuhiko Nakagawa substantially contributed to the acquisition and interpretation of data, as well as drafting and critically revising the manuscript. Masahiro Fukuoka, Satoshi Morita, Shigeru Takeshita, Kentaro Takeda, Junko Toyoshima, Itsuro Nagase, Erkut Bahceci and Maiko Morishita substantially contributed to the study design, and the analysis and interpretation of data, as well as drafting and critically revising the manuscript. All authors approved the final version to be published and agree to be accountable for all aspects of the work.